DBH

Across TCGA pan-cancer cohorts, DBH Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DBH data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DBH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DBH expression acts as an unfavorable survival marker, although some lineages such as HNSC and BLCA show a favorable association.

LIHC, SARC, and PRAD are the cancer types where DBH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
SARC	OS	Median	All	0.238	0.826	.001	6	view →
PRAD	DFS	Median	All	0.526	0.936	<.001	6	view →
HNSC	DFS	Median	III,IV	1.000	0.292	.042	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.346	0.658	.034	3	view →
BLCA	DFS	Median	III,IV	1.000	0.270	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DBH–LIHC (OS)

Open the LIHC breakdown →